Miastenija gravis udružena s timomom i aplastičnom anemijom: prikaz slučaja by Lidija Dežmalj Grbelja et al.
Acta Clin Croat 2017; 56:817-820 Case Report
doi: 10.20471/acc.2017.56.04.34
Acta Clin Croat, Vol. 56, No. 4, 2017  817
MYASTHENIA GRAVIS ASSOCIATED 
WITH THYMOMA AND APLASTIC ANEMIA: 
CASE REPORT
Lidija Dežmalj Grbelja1, Radovan Vrhovac2 and Monika Ulamec3
1University Department of Neurology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; 
2University Department of Hematology, Zagreb University Hospital Center, Zagreb, Croatia; 
3University Department of Pathology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
SUMMARY – Myasthenia gravis is associated in 10 to 15 percent of patients with thymic tumors, 
rarely with aplastic anemia. We report a 45-year-old male diagnosed with myasthenia gravis  associated 
with thymoma. We started treatment with pyridostigmine. After thymectomy, the patient  received 30 
irradiation sessions. In the postoperative course, he had mild worsening of myasthenia gravis, which 
improved with prednisone. Five months later, he developed severe aplastic anemia. He was dependent 
on blood supplement. After allogeneic transplantation of bone marrow, he improved but later he 
 developed graft versus host disease. Myasthenia gravis was under good control with 480 mg of 
 pyridostigmine per day.
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Introduction
Myasthenia gravis (MG) is an autoimmune disease 
characterized by muscle weakness which results from 
blockade of the acetylcholine receptors (AChR) by an-
tibodies and destruction of the receptors on the post-
synaptic membrane. In 10 to 15 percent of patients 
with MG, thymic tumors occur, while in 65 percent 
lymphofollicular hyperplasia of the thymic medulla is 
found. Th ymoma with malignant characteristics may 
spread locally into the mediastinum and to regional 
lymph nodes but rarely metastasizes. Th yrotoxicosis is 
seen in 5 percent of myasthenic patients, and other au-
toimmune diseases such as systemic lupus erythema-
tosus, rheumatoid arthritis, Sjögren syndrome, mixed 
connective tissue disease, polymyositis and aplastic 
anemia can be associated with MG.
Case Report
A 45-year-old male patient was admitted because 
of muscle weakness, speech and swallowing diffi  culties 
and breathing problems during physical activity per-
sisting for several months. Previous history revealed 
high-grade myopia (-10 and -16 dpt); in younger age 
he had undergone surgical treatment of inguinal and 
scrotal hernia. At the age of 43, he had experienced 
minor head trauma with anxious depressive syndrome 
as a consequence, which was an obvious reason why his 
diffi  culties initially were considered as somatization. 
He had chronic low back pain and in 2007 thyroid 
adenoma with elevated T4 was found. He had lost ap-
proximately 20 kg in the previous year. He was a non-
smoker and did not take alcohol.
He presented with ptosis of the right eyelid, re-
duced muscle strength of the right arm and both legs, 
and hypotrophy of both hands and shoulders. Diag-
nostic procedure included standard blood tests, which 
were normal including thyroid hormones, electrolytes 
and tumor markers. Brain computed tomography 
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(CT) scan was normal. Prostigmin test and repetitive 
nerve stimulation test were positive showing postsyn-
aptic dysfunction of neuromuscular junction. While 
chest x-ray was normal, CT scan of mediastinum 
showed a thymoma, 6x3.5 cm in diameter. AChR an-
tibodies were positive, which confi rmed the diagnosis 
of MG. We started treatment with pyridostigmine and 
recommended surgical extirpation of mediastinal tu-
mor, which was done two weeks later (Fig. 1). Histo-
pathologic fi nding showed infi ltration with CD3+ 
lymphocytes, immunohistochemical analysis showed 
tumor cells positive for CK7 and CK-PAN and fo-
cally positive for p-53 and blc-2, suggesting thymoma 
B1 according to the World Health Organization 
(WHO) or predominantly cortical type according to 
the classifi cation by Marino and Müller-Hermelink 
(Fig. 2). In the postoperative course, the patient had 
mild worsening of MG but improved with prednisone. 
Th en radiation therapy in a total dose of 60 Gy in 30 
fractions was administered because of infi ltration of 
the capsule and adjacent adipose tissue with tumor 
cells. CT following therapy was found to be normal. 
Five months later, he presented with petechiae, epi-
staxis and gum bleeding. Laboratory fi ndings revealed 
thrombocytopenia and anemia (erythrocytes (E) 
2.97x1012, hemoglobin (Hb) 86 g/L, platelets (Plt) 
34x109, and leukocytes (L) 7.0x109). Cytologic analysis 
of bone marrow and peripheral blood revealed inter-
mediate hematopoiesis with predominance of granu-
locytopoiesis, while megakariocytes and cells of eryth-
ropoiesis were absent. Immunologic tests did not con-
fi rm autoimmune disease. Follow up CT scan of medi-
astinum did not show any sign of residual or relapsed 
tumor mass. Th e patient was initially treated with 
methylpredinisolone in a dosage of 1 g/5 days, fol-
lowed by immunoglobulins in a dosage of 40 g/5 days, 
and fi nally with plasma exchange but without any im-
provement. Th e patient remained transfusion depen-
dent and developed iatrogenic diabetes, treated with 
gliclazide. Further treatment with azathioprine, meth-
ylprednisolone and pyridostigmine was recommended. 
Th ere was no sign of MG worsening. Two weeks later, 
fever, respiratory infection and signifi cant anemia and 
thrombocytopenia occurred. Laboratory fi ndings 
showed elevated erythrocyte sedimentation rate 
(ESR), leukopenia, anemia and thrombocytopenia 
(ESR 73, L 2.5, E 2.66, Hb 87, Plt 12). Immunologic 
tests including antinuclear antibodies (ANA), anti-
neutrophil cytoplasmic antibodies (ANCA), lupus an-
ticoagulant test, cardiolipin antibodies, rheumatoid 
factor and complement tests were normal. Cytologic 
analysis of bone marrow showed normal granulocyto-
poiesis, while erythropoiesis and thrombocytopoiesis 
were absent. Treatment with rituximab 100 mg once a 
week was started; since no improvement was noted af-
ter 4 weeks with bleeding complications and transfu-
sion dependence, a decision was made to proceed to 
bone marrow transplantation. HLA typing was done, 
followed by matched related allogeneic peripheral 
blood stem cell transplantation, with his sister being 
Fig. 1. Well-defi ned, encapsul ated grayish tumor 
with a thick fi brous capsule.
Fig. 2. Microscopically, interspersed monomorphous oval 
cells with pale round nuclei and small nucleoli surrounded 
by dispersed, densely packed population of small 
lymphocytes (HE, X400).
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the donor. He experienced acute graft versus host dis-
ease (GVHD), which was treated with corticosteroids. 
Fourteen months later, macular skin exanthema oc-
curred. Laboratory fi ndings were normal except for 
elevated liver enzymes (E 4.71, Hb 142, Plt 142, 
L10.85, aspartate transaminase 87 U/L, alanine trans-
aminase 82 U/L, gamma-glutamyltransferase 437 
U/L). Liver biopsy was done showing chronic active 
hepatitis within GVHD, which improved after corti-
costeroid treatment. Th ree months later, Epstein-Barr 
(EBV) viremia was found and he received rituximab 
until viral clearance, in order to prevent posttransplan-
tation lymphoproliferative disease. MG remained un-
der good control over the mentioned period with 480 
mg of pyridostigmine per day.
Discussion
We report a case of a 45-year-old male patient with 
a complex autoimmune neuromuscular disorder asso-
ciated with thymoma and complicated with severe 
aplastic anemia after thymectomy, which was refrac-
tory to standard medical treatment with corticoste-
roids, immunoglobulins and plasma exchange. It is 
well known that thymoma can be complicated with 
MG and that MG is associated with thymoma, but 
development of aplastic anemia in these patients is a 
rare condition. Aplastic anemia usually precedes the 
diagnosis of thymoma. Th ere have been only three 
cases described in the literature of aplastic anemia oc-
curring as a late complication after thymectomy with 
the time interval between 3 and 48 months1-3. Ritchie 
et al. described a single case of MG and aplastic ane-
mia after thymectomy and remission of thymoma4. 
Suzuki et al. found that 4 of 135 (2.9%) patients with 
MG had pure red cell aplasia (PRCA) after thymec-
tomy5. PRCA is also known as a concomitant disorder 
with MG. Th ey concluded that thymoma, bulbar in-
volvement and high level of AChR antibodies were 
signifi cantly higher in patients with PRCA. Kobayashi 
et al. report a case of a patient with MG, thymoma, 
thrombocytopenia and granulocytopenia6. After thy-
mectomy, not only the symptoms of MG but also he-
matologic fi ndings improved. Th ey also found that se-
rum level of p-ANCA against myeloperoxidase of 
granulocytes dramatically decreased after thymectomy, 
showing signifi cant correlation with the granulocyte 
count. Conclusion was that p-ANCA could be regu-
lated by thymoma, leading to severe granulocytopenia. 
According to the staging system, thymomas are classi-
fi ed as stage I when completely encapsulated, stage II 
when extending through the capsule and with pericap-
sular fat invasion, stage III when characterized by in-
vasion of adjacent structures, and stage IV when show-
ing thoracic dissemination or metastases. Th e classifi -
cation by Marino and Müller-Hermelink distinguish-
es medullary, mixed, predominantly cortical, cortical 
thymoma, well-diff erentiated thymic carcinoma, and 
other rare types of thymic carcinoma7. Th ese types dif-
fer according to invasiveness, prognosis and associa-
tion with MG. Medullary and mixed thymomas are 
rarely associated with MG, while medullary type is 
most frequently associated with hematologic disor-
ders. Cortical thymoma aff ects younger patients, shows 
more invasive nature, and is more frequently associated 
with MG. Th e occurrence of MG in a patient with 
thymoma usually precedes the diagnosis of thymic 
neoplasm. In the Mayo Clinic, 40% of 283 patients 
presented with symptoms of tumor at the time of di-
agnosis, while 46% presented with symptoms of MG. 
Out of these patients, 29% had symptoms directly re-
lated to tumor.
Complete surgical resection is the gold standard in 
the treatment of thymoma. However, in advanced 
stage, complete resection may be diffi  cult and recur-
rence is often recorded. In such cases, chemo- and ra-
diotherapy after surgical treatment improve the prog-
nosis. Also, in a tumor that is considered inoperable, 
induction radiotherapy applied before surgery im-
proves the outcome. In a retrospective study, Vassiliou 
et al. showed that patients with MG and thymoma had 
a favorable outcome and that radiotherapy could be 
omitted in totally resected stage I-II patients, whereas 
it was benefi cial in more advanced stages8. On the oth-
er hand, Mangi et al. showed that radiation did not 
prevent pleural recurrences in stage III9.
Th e course of the disease in the patient we present-
ed is interesting because he had MG associated with 
thymoma and aplastic anemia as a late complication 
after thymectomy and remission of thymoma includ-
ing a list of severe immune complications after alloge-
neic bone marrow transplantation. Despite hemato-
logic, immunologic and infectious complications, pro-
longed corticosteroid treatment probably had a favor-
able eff ect on his neuromuscular disorder, since his 
MG showed no signs of worsening over time.
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Sažetak
MIASTENIJA GRAVIS UDRUŽENA S TIMOMOM I APLASTIČNOM ANEMIJOM: 
PRIKAZ SLUČAJA
L. Dežmalj Grbelja, R. Vrhovac i M. Ulamec
Miastenija gravis (MG) je u 10% do 15% bolesnika udružena s tumorima timusa, rijetko s aplastičnom anemijom. Prika-
zujemo 45-godišnjeg bolesnika s MG udruženom s timomom. Liječenje je započeto piridostigminom. Nakon timektomije 
je provedeno 30 zračenja. Poslijeoperacijski je imao blago pogoršanje MG koje se povuklo uz terapiju prednizonom. Pet 
mjeseci kasnije je razvio tešku aplastičnu anemiju. Postao je ovisan u krvnim derivatima. Nakon alogenične transplantacije 
koštane srži došlo je do poboljšanja, ali je kasnije razvio reakciju transplantata protiv primatelja. MG je bila dobro kontroli-
rana uz 480 mg piridostigmina na dan.
Ključne riječi: Miastenija gravis; Anemija, aplastična; Timom; Piridostigmin bromid; Timektomija; Prednison; Transplanta-
cija, homologna; Transplantacijska bolest
